Medicinal cannabis was legalised in Australia in November 2016. The global legal cannabis market is expected to grow to over US$20 billion by 2020.
Come and learn about the latest trends and scientific research in this exciting new field from a range of experts.
DATE AND TIME:
Tuesday 9 May 2017
7pm - 9pm
Veterinary Science Conference Centre
Lecture Theatre 208
Paul Mavor - Health House International
Paul is a pharmacist who has been researching the potential of medicinal cannabis as a treatment for several years. His company was granted the first medicinal cannabis import license in Australia and he is currently distributing medicinal cannabis products to eligible patients. Paul brings a wealth of knowledge from his hands-on research in the U.S., Canada and Israel.
Prof David Alsopp - Sydney University
David Allsop is an Associate Professor in Psychopharmacology at the University of Sydney. David has been a leader in the medical cannabis field since 2009 when he led the development of the world’s first cannabis withdrawal measurement scale, providing a high quality measurement tool for clinicians and researchers to monitor adverse effects during medication titration. This work helped understand the clinical significance of cannabinoid withdrawal, leading to its inclusion in the DSM-5 for the first time. David led Australia’s first ever-clinical trial administering a cannabis-based medicine to humans, using Sativex as a Cannabinoid Replacement Therapy. David is currently a Director in the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, setting strategic clinical direction to encourage and support research and community awareness for cannabis based medicines.
Ben Oakley- Patient Advocate
Ben is one of only 20 people in Australia suffering from "Stiff Person Syndrome". He will explain his journey and his fight to access medicinal cannabis.
Rhys Cohen - Cann10 Australia
Rhys is a political economist, industry expert and educator. Since leading the team behind the first Australian medicinal cannabis industry White Paper, he has consulted on a variety of commercial projects and is now the Program Director at Cann10 Australia which will be running the country’s first comprehensive medicinal cannabis education program later this year. Rhys will be discussing the emergence of the Australian industry as well as current global trends in legal cannabis markets.
- Seminar may qualify for Continuing Education (CE/CPD) points and includes an optional 5 question multiple choice test.